---
figid: PMC7215415__ijms-21-02773-g001
figlink: pmc/articles/PMC7215415/figure/ijms-21-02773-f001/
number: F1
caption: 'Chemotherapeutic agents in CRC. (A) 5-FU activates p38α and β isoforms leading
  to cell death, and the p38δ MAPK isoform, though MKK3 activation, leading to cell
  survival. Depletion of p38δ MAPK by RNA interference (siRNA) exerts antitumor effects.
  (B) Oxaliplatin induces apoptosis in CRC through p38 MAPK signaling pathway activation.
  The hyperactivation of p38 MAPK signaling supports oxaliplatin-resistance in CRC.
  Pharmacological p38 MAPK inhibition (SB 202190) re-sensitizes CRC cells to drug
  response. (C) Irinotecan (CPT-11) induces p38 MAPK activation dose dependently exerting
  different therapeutic outcomes in CRC: high dosage CPT-11 induces acute and short-lasting
  p38 MAPK activation leading to apoptosis; low dosage CPT-11 activates p38 MAPK in
  a delayed but sustained manner promoting cell-survival. Up arrows show levels of
  p38 activation via phosphorylation; down arrows show workflow of cell signaling;
  T bars represent inhibitory actions via siRNAs or chemicals.'
pmcid: PMC7215415
papertitle: The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic
  Treatments.
reftext: Angelina Pranteda, et al. Int J Mol Sci. 2020 Apr;21(8):2773.
pmc_ranked_result_index: '2966'
pathway_score: 0.9154145
filename: ijms-21-02773-g001.jpg
figtitle: Chemotherapeutic agents in CRC
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7215415__ijms-21-02773-g001.html
  '@type': Dataset
  description: 'Chemotherapeutic agents in CRC. (A) 5-FU activates p38α and β isoforms
    leading to cell death, and the p38δ MAPK isoform, though MKK3 activation, leading
    to cell survival. Depletion of p38δ MAPK by RNA interference (siRNA) exerts antitumor
    effects. (B) Oxaliplatin induces apoptosis in CRC through p38 MAPK signaling pathway
    activation. The hyperactivation of p38 MAPK signaling supports oxaliplatin-resistance
    in CRC. Pharmacological p38 MAPK inhibition (SB 202190) re-sensitizes CRC cells
    to drug response. (C) Irinotecan (CPT-11) induces p38 MAPK activation dose dependently
    exerting different therapeutic outcomes in CRC: high dosage CPT-11 induces acute
    and short-lasting p38 MAPK activation leading to apoptosis; low dosage CPT-11
    activates p38 MAPK in a delayed but sustained manner promoting cell-survival.
    Up arrows show levels of p38 activation via phosphorylation; down arrows show
    workflow of cell signaling; T bars represent inhibitory actions via siRNAs or
    chemicals.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK14
  - MAPK11
  - MAPK13
  - MAPK12
  - 5-FU
  - IRINOTECAN
  - CPT-11
  - SB 202190
genes:
- word: p-p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: p-p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: p-p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: p-p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
chemicals:
- word: 5-FU
  source: MESH
  identifier: D005472
- word: IRINOTECAN
  source: MESH
  identifier: C051890
- word: CPT-11
  source: MESH
  identifier: C051890
- word: SB 202190
  source: MESH
  identifier: C090942
diseases: []
figid_alias: PMC7215415__F1
redirect_from: /figures/PMC7215415__F1
figtype: Figure
---
